Outlook Therapeutics Inc

NASDAQ:OTLK   3:59:58 PM EDT
1.48
+0.04 (+2.78%)
Regulatory, Other Pre-Announcement

Outlook Therapeutics Reports Completion Of Patient Dosing In The Ons-5010 Pivotal Phase 3 Norse Two Trial

Published: 06/08/2021 12:32 GMT
Outlook Therapeutics Inc (OTLK) - Outlook Therapeutics Reports Completion of Patient Dosing in the Ons-5010 Pivotal Phase 3 Norse Two Trial.
Outlook Therapeutics Inc - Topline Data Are Expected to Be Reported for Norse Two in Third Calendar Quarter of 2021.
Outlook Therapeutics - Look Forward to Planned New Bla Submission for Wet Amd in Q1 of Calendar 2022.
Outlook Therapeutics - Expects to Initiate Registration Clinical Trials for Ons-5010 for Dme and Brvo Later in Calendar 2021 Or in Early Calendar 2022.